Tag: NSB

NeuroScientific Biopharmaceuticals ASX NSB Copaxone myelin formation MS model EmtinB Multiple sclerosis

NeuroScientific hails potential breakthrough after early EmtinB study results

NeuroScientific Biopharmaceuticals (ASX: NSB) has published positive preliminary results from a pre-clinical study of its lead compound EmtinB in treating multiple sclerosis (MS). The full report i...
Multiple Sclerosis NeuroScientific Biopharmaceuticals ASX NSB EmtinB

NeuroScientific’s EmtinB drug achieves positive results in pre-clinical MS research

NeuroScientific Biopharmaceuticals (ASX: NSB) has achieved positive results in pre-clinical studies using its lead drug candidate EmtinB to treat multiple sclerosis models. Independent research org...
NeuroScientific Biopharmaceuticals glaucoma pig model neuroprotective effect EmtinB ASX NSB

NeuroScientific Biopharmaceuticals posts positive outcomes from glaucoma study on animal models

NeuroScientific Biopharmaceuticals (ASX: NSB) has revealed positive results from a glaucoma study on pig models that indicates the “disease-modifying potential” of its lead drug candidate EmtinB. T...
NeuroScientific Biopharmaceuticals ASX NSB Glaucoma EmtinB retina optic nerve

NeuroScientific reveals positive results from pre-clinical glaucoma study

Drug developer NeuroScientific Biopharmaceuticals (ASX: NSB) has revealed the first pre-clinical results of an ophthalmology program that has demonstrated the potential for its lead drug candidate Emt...
NeuroScientfic Biopharmaceuticals ASX NSB drug candidate Alzheimers

NeuroScientific publishes positive results in fight against Alzheimer’s

Alzheimer’s treatment could be set for a significant boost following the publication of what NeuroScientific Biopharmaceuticals (ASX: NSB) calls a “breakthrough study” into its lead drug candidate Emt...
NeuroScientific Biopharmaceuticals ASX NSB IPO Alzheimers dementia brain injury stroke

NeuroScientific Biopharmaceuticals goes public with its novel EmtinB treatment for Alzheimer’s disease

There is yet more hope for Alzheimer’s sufferers as biopharma solutions continue to make their way onto the ASX for funding and wider recognition. Pharmaceutical company NeuroScientific Biopharmace...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS